Clinical Trial Update: Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension) [Phase 4]

View source ↗

Summary

This Phase 4 extension study (CLARIFY MS Extension) evaluated cognition and health-related quality of life in adults with highly-active relapsing multiple scler…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MAVENCLAD (cladribine)

Snippet

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2024-05-28